About This Talk
Deepa Prasad is Managing Director at WestRiver Group (WRG) where she leverages her 20 years of investing and operations experience to guide healthcare investments in biotech and digital health / AI.
Deepa's investments include Design Therapeutics, a gene-targeted platform company and Ginger, 24/7 digital health access for behavioral care and Viome, a gut biome company focused on precision medicine where she serves on the Board.
Her prior experience includes Chief of Staff at Blue Shield, Regional Vice President for Optum, Head of Managed Care at California Hospital Association, VP Financial Strategy and Business Development at Coherus Biosciences and healthcare investment banking and consulting for her first 10 years.
Deepa currently serves on the Committee for Innovation and Entrepreneurship at UC Davis awarding grant funding to scientific research and as a Charter Member for TiE, a non-profit global network of entrepreneurs and VCs where she mentors startup companies.
Prelude Growth Partners
Alicia is a strategic and innovative leader who has driven the growth of leading consumer brands.
Prior to founding Prelude Growth Partners, Alicia was Global President of Beauty at Johnson & Johnson, leading a multi-billion dollar portfolio of 10+ iconic global brands. Prior to that, she was an executive at Estee Lauder for 11 years, including leadership roles at Bobbi Brown and Clinique. Alicia began her career at McKinsey & Company where she spent 5 years serving consumer clients. Alicia is a summa cum laude graduate of The Wharton School and she earned her MBA from Harvard Business School.
Garheng founded HealthQuest Capital in 2012 to improve people's lives through improving healthcare on a significant scale. His vision was to build a best-in-class team of the highest talent and integrity to work with outstanding entrepreneurs to transform healthcare through high growth companies while generating outsized risk adjusted returns for investors.
A physician, scientist, and engineer by training, Garheng has over two decades of experience investing in innovative healthcare companies with a long list of successes (25 IPO/M&A exits). He has represented HealthQuest on the boards of Ajax I, Ajax II, Ajax III, Alcresta, Avedro, Avizia, BardyDx, Castle Biosciences, CleanSlate, Etairos, ENT Specialty Partners, Everlywell, HealthChannels, Magnolia Medical, Perspectum, Pulmonx, Spirox, TigerConnect, Trice Medical, Venus Concept, and CareMetx/VirMedica.
Some of his notable past successes include IPO's with Avedro (AVDR), Castle Biosciences (CSTL), Cempra (CEMP), Alimera (ALIM), Applied Genetic Technology Corp. (AGTC), AmWell (AMWL), Proteon (PRTO), Pulmonx (LUNG), Histogenics (HSGX), TransEnterix (TRXC) and Venus Concept (VERO). His investments going on to successful M&A transactions include: Ajax I (Medtronic), Avedro (Glaukos), Avizia (AmWell), Calibra Medical (J&J), Cellective (AstraZeneca), Serenex (Pfizer), Athenix (Bayer), NovaMin (GSK), Aldagen (Cytomedix), Salveo Specialty Pharmacy (United Health), SARCode (Shire), Spirox (Stryker), and Virmedica (CareMetx).
Garheng's interests and industry footprint are broad as he also serves on boards of LabCorp (LH), Alimera Sciences (ALIM), StrongBridge (SBBP), Be The Match, Duke University Medical Center, and has served as Chairman on nine boards. He is an Aspen Institute Health Innovators Fellow, Kauffman Fellows Mentor, and member of YPO.
Garheng received undergraduate degrees in both Chemical Engineering and Biological Sciences from Stanford, while on an athletic scholarship. He then earned a MD, PhD and MBA from Duke University, graduating at the top of his class in each instance. His early career included stints at GlaxoSmithKline, McKinsey and a medical device start-up, TherOx, before joining Intersouth Partners and then Sofinnova Investments. He is married to his physician wife (a board certified cardiac electrophysiologist), has 3 children, and was a nationally ranked volleyball player (and avid "foodie").
Advance Venture Partners
David ibnAle is a Founding and Managing Partner of Advance Venture Partners. He has over twenty years of experience as an investor in small and mid-sized growth companies in the technology, media and communications sectors. Prior to co-founding AVP, Mr. ibnAle was a Managing Director of TPG Growth, the growth equity and middle-market investment platform of TPG, where he led the firm's global technology investing effort. Prior to joining TPG Growth, he was a Partner at Francisco Partners, and he began his investing career at Summit Partners. Mr. ibnAle is a member of the Board of Directors of publicly held UCT Holdings (Nasdaq: UCTT).
Mr. ibnAle received an AB in Public Policy and an AM in International Development Policy from Stanford University and received an MBA from the Stanford University Graduate School of Business.